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Flemingia macrophylla (Leguminosae), a native plant of Taiwan, is used as folk medicine. An in vitro study showed that a 75%
ethanolic extract of F. macrophylla (FME) inhibited osteoclast diﬀerentiation of cultured rat bone marrow cells, and the active
component, lespedezaﬂavanone A (LDF-A), was isolated. It was found that oral administration of FME for 13 weeks suppressed
bone loss in ovariectomized rats, an experimental model of osteoporosis. In addition, FME decreased urinary deoxypyridinoline
concentrations but did not inhibit serum alkaline phosphatase activities, indicating that it ameliorated bone loss via inhibition of
bone resorption. These results suggest that FME may represent a useful remedy for the treatment of bone resorption diseases, such
as osteoporosis. In addition, LDF-A could be used as a marker compound to control the quality of FME.
1.Introduction
Osteoporosis is a major health problem in aging com-
munities. Osteoporosis signiﬁcantly increases the frequency
fractures, and hip fracture in elderly patients is a very
serious problem because it can limit the patient’s quality of
life. Bisphosphonates are currently the major drugs used to
treat osteoporosis. However, they are associated with side
eﬀects as esophageal cancer and osteonecrosis of the jaw
[1]. Therefore, it is still valuable to develop safer preventive
medicine to suppress osteoporosis.
Osteoporosis is caused by an imbalance between bone
resorption and bone formation, which results in bone loss
and fractures after mineral ﬂux [2]. Bisphosphonates are
bone resorption inhibitors that maintain bone mass by
inhibiting the function of osteoclasts [3]. Osteoclasts are the
primary bone-resorbing cells and hematopoietic in origin,
and their diﬀerentiation is induced by the local production
of various cytokines, receptor activator of nuclear factor κB
ligand (RANKL), and macrophage colony-stimulating factor
(M-CSF) [4, 5]. Thus, osteoclast formation in bone marrow
cells may be applicable in the screening of osteoporosis
medicines.
On the other hand, herbal medicine has been widely
used for the treatment of rheumatism and bone disease. The
root and stem of the herbal plant Flemingia macrophylla
(Leguminosae) are recommended in Taiwan for the manage-
ment of rheumatoid arthritis and bone disease, such as low-
back pain in climacteric and senescent periods. Uncontrolled
osteoclastogenesis is observed in rheumatoid arthritis, which
is accompanied with signiﬁcant bone resorption [6]. In cases
of high-bone destruction, the function and diﬀerentiation
of osteoclasts are highly upregulated. It has been suggested
that the eﬀectiveness of oriental medicines on low-back pain
seems to be due to their eﬃcacy in curing osteoporosis [7].
However, no data are available with regard to the recovery of
bone mass by F. macrophylla.
In postmenopausal women, estrogen deﬁciency leads to
the most common form of osteoporosis. Several medications
have also been reported to be clinically eﬀective in curing
osteoporosis based on results obtained from nonsteroidal
sources, such as bisphosphonates and calcitonin, using
animalmodels[8].Investigatingpostmenopausalosteoporo-
sis using ovariectomized (OVX) rats is useful to evaluate
osteoporosis drugs. In this study, we investigated the eﬀects
of FME on osteopenia in OVX rats.
2. Methods
2.1. Plant Extract Preparation. Roots and stems of F. macro-
phylla were purchased from a local market in Taichung,2 Evidence-Based Complementary and Alternative Medicine
Taiwan.TheplantswereidentiﬁedbytheInstituteofChinese
Pharmaceutical Sciences, China Medical University, where
voucher specimens have been deposited.
Flemingia macrophylla roots and stems were extracted
twice with 75% ethanol, followed by evaporation of the
solvent under reduced pressure at 50◦C. The ethanolic
extract (FME) yield was 7.8%. The FME dosage used in the
experiments was based on the dry weight of the extract. FME
was suspended in distilled water and administered orally to
each rat with a volume of 1ml/100g body weight.
2.2. Isolation and Determination of the Active Compound.
FME was suspended in water and partitioned with n-
butanol. The n-butanol fraction (FMB) was concentrated,
yielding 2.8%. FMB (75g) was suspended in water and
partitionedwithchloroform.Thechloroformfraction(yield,
21.6g) was chromatographed on a silica gel (Si 60 F245;
Merck, Germany) using hexane/ethyl acetate (80 : 20–0
: 100) to obtain 10 fractions (I–X). Fraction IV (6.1g)
was rechromatographed on a silica gel ODS-18 column
(LiChroprep RP-18; Merck) and eluted with methanol/H2O
(1 : 1–9 : 1) to obtain eight subfractions (a–h). Fraction IV-c
(370mg)wasappliedtopreparativehigh-performanceliquid
chromatography (HPLC) to yield a pure compound (75mg).
The conditions for preparative HPLC were as follows: pump,
Shimadzu LC-8A (Kyoto, Japan); mobile phase, hexane/ethyl
acetate (9 : 1); column, PEGAAIL Silica 60-5 (i.d. 10mm,
250-mm long; Senshu Scientiﬁc, Tokyo, Japan). The pure
compound was identiﬁed using mass spectroscopy (HP
5995C;USA).Extensivenuclearmagneticresonanceanalyses
(1H, 13C, DEPT, COXY, HMQC, HMBC; Bruker 400MHz,
Germany) identiﬁed the compound as lespedezaﬂavanone
A( L D F - A )[ 5 ,7 ,2  -trihydroxy-6, 8-di-r, r-dimethylallyl-4 -
methoxyﬂavanone] (Figure 1), which had been previously
isolated by Wang and Li [9]. 13Ca n d1H NMR spectra of
L D F - Aw e r ea sf o l l o w s :1HN M R( a c e t o n e - d6): δ 1.61 (3H,
s, H-4  ), δ 1.62 (3H, s, H-5  ), δ 1.65 (3H, s, H-4   ), δ 1.75
(3H, s, H-5   ), δ 2.79 (1H, dd, J = 17.1, 2.9Hz, H-3), δ 3.09
(1H, dd, J = 16.8, 12.9Hz, H-3), δ 3.31 (2H, d, J = 7.4Hz,
H-1  ), δ 3.33 (2H, d, J = 7.1Hz, H-1   ), δ 3.76 (3H, s),
δ 5.17 (1H, m, H-2  ), δ 5.19 (1H, m, H-2   ), δ 5.68 (1H,
dd, J = 12.8, 2.9Hz, H-2), δ 6.52 (1H, d, J = 2.1Hz, H-3 ),
δ 6.52 (1H, dd, J = 9.3, 2.4Hz, H-5 ), δ 7.43 (1H, d, J =
6.8Hz, H-6 ).13CN M R( a c e t o n e - d6): δ 17.07 (C-4  ,C - 4    ),
20.06 (C-1  ), 20.94 (C-1   ), 25.01 (C-5  ,C - 5    ), 41.86 (C-
3), 54.63 (C-4 -OCH3), 74.35 (C-2), 101.48 (C-5 ), 102.44
(C-10), 105.00 (C-3 ), 107.11 (C-6), 107.80 (C-8),118.24 (C-
1 ), 122.51 (C-2   ), 122.65 (C-2  ), 127.73 (C-6 ), 131.07 (C-
3   ), 131.28 (C-3  ), 155.31 (C-2 ),158.44 (C-4 ), 159.33 (C-
7), 160.85 (C-5), 161.42 (C-9), and 197.42 (C-4).
LDF-A content was determined by HPLC. The condi-
tions for HPLC were as follows: pump, Shimadzu LC-6A;
UV spectrophotometric detector, SPD-6AV; and column,
Cosmosil 5C18-AR-II column (i.d. 4.6mm, 250-mm long;
Nacalai Tesque, Tokyo, Japan). The mobile phase consisted
of two elutions programed as a linear gradient of water with
0.2% acetic acid (A) and acetonitrile (B) at a ﬂow rate of
0.3ml min−1 (t = 0 minutes, 30% A; t = 17 minutes, 20% A; t
HO
OH O
O
HO OCH3
Figure 1: Structure of lespedezaﬂavanone A.
= 40 minutes, 20% A, and next injection). UV detection was
performed at 270 nm. LDF-A content in FME was 0.26%.
2.3. Mature Osteoclast Diﬀerentiation Assay. Bone marrow
cells were prepared by removing bone marrow from the
femoraandtibiaeofWistarratsweighing250–300gandthen
ﬂushing the bone marrow cavity with α-minimum essential
medium (Hyclone, Logan, UT, USA) supplemented with
20mM HEPES, 10% heat-inactivated fetal bovine serum,
2mM glutamine, penicillin (100Uml−1), and streptomycin
(100μgml −1). The nonadherent cells (hematopoietic cells)
were collected after 24 hours and used as osteoclast pre-
cursors. Cells were seeded at 1 × 106 cells/well in 24-
well plates in the presence of human recombinant soluble
RANKL (50ngml−1; PeproTech EC, London, UK) and M-
CSF (20ngml−1; PeproTech EC). Various concentrations
of FME or LDF-A were added to these cultures. The
culture medium was replaced with fresh medium every 3
days. Osteoclast formation was measured using the tartrate-
resistant acid phosphatase (TRAP) staining kit on day 9 [10].
Brieﬂy, adherent cells were ﬁxed with 10% formaldehyde
in phosphate-buﬀered saline (PBS) for 3 minutes and
then stained with Naphthol AS-Mx phosphate and tartrate
solution for 1 hours at 37◦C. TRAP-positive cells with more
than three nuclei were scored as osteoclasts [11]. To clarify
the action of LDF-A, eﬀect of cotreatment with ICI 182780
(1nM), an estrogen receptor (ER) antagonist [12], on the
osteoclastogenesis was also investigated.
2.4. Animals. Wistar rats were obtained from BioLASCO
(Taipei, Taiwan) and housed in an air-conditioned room at
21–24◦C with 12 hours of light. The rats had free access
to food pellets and water throughout the study period.
All the animal experiments were conducted according to
the guidelines established by the Animal Care and Use
Committee of China Medical University and were approved
by this committee.
2.5. Animal Experiments. Female rats were anesthetized with
pentobarbital sodium (40mgkg−1, i.p.), and their ovaries
were removed bilaterally. The rats in the sham-operatedEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Eﬀe c t so fF M Eo no s t e o c l a s t o g e n e s i si nr a tb o n em a r r o w
culture system. All values are mean ± SD (n = 3). ∗P < .05, ∗∗P <
.01, ∗∗∗P < .001 compared with the control group.
group were anesthetized, laparotomized, and sutured with-
out removing their ovaries. After 1 week of recovery from
surgery,theOVXratswererandomlydividedintoﬁvegroups
and orally treated with H2O, FME (50, 250 or 500mgkg−1
daily), or alendronate (2.5mgkg−1 daily; Sigma-Aldrich, St
Louis, MO, USA) for 13 weeks. The sham-operated group
was orally treated with H2O. The body weight of each
animal was measured once a week until the ﬁnal day of
administration.
Sixteen-hour urine samples were collected after 13 weeks
of treatment. On the last day of the study, the animals
were sacriﬁced under deep anesthesia with a high dose of
pentobarbital sodium (65mgkg−1, i.p.), and blood samples
were collected simultaneously. The tibiae and lumbar ver-
tebrae were dissected. Each left tibia was submerged in 4%
neutral-buﬀered paraformaldehyde solution and processed
to prepare sections for pathological examination. The other
dissectedbones werestored at −80◦C until examination. The
vaginae were dissected out and immediately weighed.
2.6. Biochemistry. Serum alkaline phosphatase and urinary
creatinine were assayed using clinical test kits (Roche
Diagnostics, Mannheim, Germany) in a spectrophotometric
analyzer (Cobas Mira Plus; Roche, Rotkreuz, Switzerland).
Serum calcium (Ca) and urinary Ca were measured by the
o-cresolphthalein complexone method using a commercial
kit (Randox, UK). Urinary Ca contents were expressed as
milligrams per millimole of urinary creatinine. Urinary
deoxypyridinoline (DPD) contents were determined by
enzyme immunoassays using a commercial kit (Metra, San
Diego, CA, USA). DPD contents in urine samples were
expressed as milligrams per millimole of urinary creatinine.
2.7. Measurement of Bone Mineral Content (BMC) and
Bone Mineral Density (BMD). The BMC and BMD of
each right tibia were measured using a dual-energy X-ray
absorptiometer (XR-26; Norland, Fort Atkinson, WI, USA)
using a model for small subjects.
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Figure 3: Eﬀect of LDF-A alone and cotreatment with ICI 182
780 (a 17β-estradiol antagonist) on osteoclastogenesis in a rat bone
marrowculturesystem.Allvaluesaremean ±SD(n =3). ∗∗P <.01,
∗∗∗P < .001 compared with the control group. #P < .05 compared
with 17β-estradiol group by t-test.
2.8. Measurement of Bone Ash and Ca Content. Each ﬁfth
lumbar vertebra was desiccated in diﬀerent baths of alcohol
and dried overnight at 100◦C. The dry weight was then
determined. Next, the vertebra was incinerated for 12
hours at 1000◦C, and the ash weight was determined. The
measurements obtained were expressed as the percentages of
the ash amounts relative to the dry weight of the vertebra.
Theashwasthensolubilizedin6NHClandanalyzedusinga
Ca assay. Values were expressed as milligram of Ca per cubic
centimeter of bone volume. Bone volume was measured by
Archimedes principle [13].
2.9. Histological Studies of the Tibiae. The left tibiae were
removed, ﬁxed with 4% neutral-buﬀered paraformaldehyde
in PBS (pH 7.4) for 48 hours, and decalciﬁed in 10%
ethylenediamine tetraacetic acid solution (pH 7.4) at 4◦C
for 4 weeks. After decalciﬁcation, each bone sample was
cut along the coronal plane, embedded in paraﬃn, and cut
longitudinally into sections for histological staining. After
staining with hematoxylin and eosin, sections were observed
for microarchitectural changes under a microscope. The
captured images were analyzed using a color image analysis
system (Image-Pro Plus version 5.1; Media Cybernetics, MD,
USA). The trabecular bone volume and cortical thickness of
the metaphysis were measured. The trabecular bone volume
was expressed as a percentage of the total tissue area at the
sampling site [14]. For measurement of the osteoclast num-
ber, sections were stained for TRAP with TRAP kit (Sigma-
Aldrich, St. Louis, MO, USA) as previously described [10].
2.10. Statistical Analysis. Results were expressed as mean
± SD. All experimental data were analyzed using one-way4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀects of FME on body weight and weight of vigina in OVX rats.
Drugs Dose (mgkg−1) Body weight (g) Vaginal (g)
Week 0 Week 13
Sham — 267.1 ± 13.6 289.6 ± 19.0∗∗∗ 0.50 ± 0.04∗∗∗
OVX + H2O — 260.0 ± 22.7 372.8 ± 30.7 0.17 ± 0.02
OVX + FME
50 263.7 ± 18.4 378.8 ± 34.2 0.18 ± 0.02
250 263.8 ± 23.0 369.1 ± 27.6 0.17 ± 0.03
500 260.3 ± 18.0 374.8 ± 25.7 0.17 ± 0.02
OVX + Alen 2.5 266.6 ± 20.1 377.8 ± 36.5 0.18 ± 0.01
All values are mean ± SD (n = 8). Alen, alendronate.
∗∗∗P < .001, versus the OVX + H2Og r o u p .
Table 2: Eﬀects of FME on serum alkaline phosphatase activity and urinary Ca and DPD contents in OVX rats.
Drugs Dose ALP Urinary Ca Urinary DPD
(mgkg−1)( I U l −1) (mgmmol−1 Crea.) (nmol mmol−1 Crea.)
Sham — 120.6 ± 24.6∗∗ 39.7 ± 21.0∗∗ 292.4 ± 58.7∗∗∗
OVX + H2O — 167.1 ± 25.0 89.3 ± 40.3 520.7 ± 97.0
OVX + FME
50 160.9 ± 38.5 52.5 ± 12.4 444.7 ± 104.2
250 156.3 ± 12.5 39.3 ± 20.3∗ 384.5 ± 106.2∗
500 150.6 ± 20.0 37.3 ± 15.3∗∗ 380.4 ± 69.5∗
OVX + Alen 2.5 163.5 ± 24.0 45.2 ± 14.8∗∗ 281.2 ± 52.3∗∗∗
All values are mean ± SD (n = 8). Alen, alendronate; ALP, alkaline phosphatase; Crea., creatinine.
∗ P < .05, ∗∗P < .01, ∗∗∗P < .001, versus the OVX + H2Og r o u p .
analysis of variance with Dunnett’s test. Values of P < .05
were considered statistically signiﬁcant.
3. Results
3.1. Osteoclast Formation from Rat Bone Marrow Cells. The
formation of large TRAP-positive multinucleated osteoclasts
in bone marrow-derived stromal cell cultures in the presence
of M-CSF and RANKL was dose-dependently inhibited
by FME (100–500μgml −1)a n dL D F - A( 1 0 −7 to 10−5 M)
(Figures 2 and 3). In addition, 17β-estradiol (10nM),
a positive control drug, showed an inhibitory eﬀect on
osteoclastogenesis of rat bone marrow cells (Figure 3).
Cotreatment with ICI 182 780 at 1nM signiﬁcantly blocked
the inhibition of osteoclastogenesis induced by 17β-estradiol
(Figure 3). However, ICI 182 780 did not reverse these
actions of LDF-A (Figure 3). ICI 182 780 alone at 1nM
inhibited osteoclastogenesis by 4%.
3.2. Body and Organ Weights. The rats in all of the six exper-
imental groups had similar initial body weights. Thirteen
weeks after the operation, the OVX rats showed signiﬁcant
increases in body weight. The increased body weight of
the OVX rats was not aﬀected by FME or alendronate
administration (Table 1).
The vaginal weights signiﬁcantly decreased in the OVX
rats compared with the sham-operated rats. Decreased
vaginal weights in the OVX rats were not aﬀected by FME
or alendronate administration (Table 1).
3.3. Plasma Alkaline Phosphatase Activity and Urinary Ca
and DPD Contents. Ovariectomy induced an increase in the
plasmaalkalinephosphataseactivity.TreatmentwithFMEor
alendronate did not aﬀect the plasma alkaline phosphatase
activity (Table 2).
Ovariectomy resulted in a signiﬁcant increase in urinary
Ca and DPD contents in the OVX rats. FME (250 and
500mgkg−1) or alendronate administration suppressed the
increase in urinary Ca and DPD contents in OVX rats
(Table 2).
3.4. BMC and BMD. The tibial BMC and BMD were 29.5
and 14.3% lower in the OVX group than in the sham group,
respectively. Treatment with FME (250 and 500mgkg−1)o r
alendronate signiﬁcantly prevented reductions in BMC and
BMD (Figure 4).
3.5. Bone Ash Ratio and Bone Ca Content. The ash weight
ratio and Ca content of the ﬁfth lumbar vertebra were 15.7
and18.1%lowerintheOVXgroupthaninthecontrolgroup,
respectively. Administration of FME (250 and 500mgkg−1)
or alendronate caused signiﬁcant increase in the ash weight
ratio and Ca content of the ﬁfth lumbar vertebra compared
with the OVX control group (Figure 5).
3.6.BoneHistology. Thetrabecularbonev olumeandcortical
thickness of the metaphysis were considerably lower in the
OVX rats than in the sham rats. FME and alendronate treat-
ments signiﬁcantly increased the trabecular bone volumeEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀects of FME on the BMC and BMD of the right tibia in OVX rats. All values are mean ± SD (n = 8). ∗P < .05, ∗∗∗P < .001
compared with the OVX + H2O group.
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Figure 5: Eﬀects of FME on the ash weight ratio and Ca content of the ﬁfth lumbar vertebra in OVX rats. All values are mean ± SD (n = 8).
∗P < .05, ∗∗P < .01, compared with the OVX + H2O group.
and cortical thickness of the metaphysis in the OVX rats
(Figure 6).
The number of osteoclasts in the region of the primary
spongiosa signiﬁcantly increased in the OVX rats. FME and
alendronate treatments decreased the number of osteoclasts
in the OVX rats (Figure 7).
4. Discussion
The study has shown that orally administered FME is able
to prevent osteoporosis in OVX rats. In addition, its active
component, LDF-A, was isolated from FME and found to
inhibit osteoclastogenesis in vitro, suggesting that it may be
useful as a standard compound for FME preparation.
Osteoclasts are generated from hematopoietic cells of the
monocyte/macrophage lineage [5]. Several lines of evidence
have indicated that two key molecules, M-CSF and RANKL,
are essential and suﬃcient to promote osteoclastogenesis
[11]. We used this osteoclast diﬀerentiation system to
examine the actions of FME and found that it suppressed
osteoclast formation. On the basis of the bioactivity-guided
fractionationprinciple,wefurtherisolatedtheactivecompo-
nent, LDF-A, from FME. LDF-A suppressed the formation
of osteoclasts in cultured rat bone marrow cells in a dose-
dependent manner. LDF-A could be used as a marker
component for antiosteoporosis therapies involving FME.
We also determined that the amount of LDF-A in FME was
0.26%.
Phytoestrogens are a group of biologically active plant
substances with a chemical structure similar to that of
estradiol, an endogenous estrogen. This structural similarity
accounts for the ability of these compounds to bind to ERs6 Evidence-Based Complementary and Alternative Medicine
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Figure 6:Histologicalanalysis ofthebonesectiononleft tibiae.(a)Sham-operated group.(b)OVX+H2Ogroup.Theseratsshowdecreases
in the trabecular bone and cortical thickness of the metaphysis. (c) OVX + FME (500mgkg−1) group. These rats show increases in the
trabecular bone and cortical thickness of the metaphysis. (d) OVX + alendronate group. These rats show increases in the trabecular bone
and cortical thickness of the metaphysis. Magniﬁcation = 40x. (e) Histogram representing image-quantization of the mean percentage of
trabecular volume/tissue volume (BV/TV) and (f) cortical thickness (Cort. Th) of the metaphysic. All values are mean ± SD (n = 8). ∗P <
.05, ∗∗P < .01, ∗∗∗P < .001 compared with the OVX + H2O group.
and exert various estrogenic or antiestrogenic eﬀects [15].
There are three main classes of phytoestrogens: isoﬂavones,
coumestans, and lignans, which occur in either plants or
seeds [15]. Kuiper et al. [16] reported that the binding
aﬃnity of naringenin (ﬂavanone) for ERβ was 0.11, whereas
that of genistein (isoﬂavone) and kaemferol (ﬂavonol) was
87 and 3, respectively, when the binding aﬃnity for estradiol
was arbitrarily set at 100. The aﬃnity of LDF-A may be low,
because LDF-A belongs to the same group (ﬂavanone) as
naringenin.Inthisstudy,wealsoobservedthattheinhibitory
action of LDF-A on osteoclastogenesis was not abolished
by ICI 182 780, an ER antagonist [12], indicating that theEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: Histological analysis of the number of osteoclasts on the left tibiae. (a) Sham-operated group. (b) OVX + H2O group. These rats
show an increase in the number of osteoclasts (arrows). (c) OVX + FME (500mgkg−1) group. These rats show a decrease in the number of
osteoclasts (arrows). (d) OVX + alendronate group. These rats show a decrease in the number of osteoclasts (arrows). Magniﬁcation = 200x.
(e) Histogram representing the osteoclast number/mm bone surface (N. Oc/BS). All values are mean ± SD (n = 8). ∗∗∗P < .001 compared
with the OVX + H2O group.
inhibitory action of LDF-A on osteoclastogenesis was not
dependent on the ER.
To evaluate the eﬃcacy of FME for the treatment of
postmenopausal osteoporosis, a rat OVX model was used in
this study. Because of the ovarian hormone deﬁciency, there
was an increase in body weight and a decrease in vaginal
weight in the OVX rats, consistent with a previous study
[17]. ER exists in two main forms, ERα and ERβ,w h i c h
have distinct tissue expression patterns in both human and
rodents [18]. Evidence shows that the selective activation of
ERα decrease food intake and body weight, body fat, and
increase vaginal weight and blood ﬂow in OVX animals [19–
21]. FME did not treat the postmenopause associated with
obesity and vaginal atrophy, indicating that FME did not
exert ERα agonist activity.
The OVX model has been used as an animal model
for stimulating various clinical syndromes derived from
osteoporosis [8]. In this study, histological examination8 Evidence-Based Complementary and Alternative Medicine
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Figure 8: The proposed antiosteoporotic mechanism for FME. FME inhibits the diﬀerentiation of bone marrow monocytes to osteoclasts
to ameliorate the osteoporosis induced by ovariectomy in mice.
furtherrevealedthatthetrabecularbonevolumeandcortical
thickness of the metaphysis of the tibia decreased in the OVX
rats. In addition, bone loss was manifested by reductions
in the tibial BMC and BMD in the OVX rats. Treatment
with FME signiﬁcantly reduced this bone loss in the OVX
rats. Bone mineral components, such as Ca, decreased in
the ﬁfth lumbar vertebra of the OVX rats, whereas urinary
excretion of Ca was elevated in the OVX rats [22]. These
results conﬁrm that Ca deposition decreased in OVX rats.
FME treatment also improved the loss of Ca content in the
OVX rats. These results clearly show that FME treatment in
rats can ameliorate osteopenia induced by ovariectomy.
The serum activity of alkaline phosphatase, an index of
bone formation [23], has been reported to be signiﬁcantly
greater in an OVX group than in a sham-operated group
[24]. A similar change was observed in this study. FME
treatment did not aﬀect the activity of serum alkaline
phosphatase. DPD is a marker of bone resorption [25].
OVXincreasedtheurinaryDPDcontent,whichdecreasedby
FME treatment. These results suggest that FME ameliorated
the bone loss induced by ovariectomy by inhibiting bone
resorption, rather than enhancing bone formation.
Osteoclasts are multinucleated cells of hematopoietic
origin and comprise primary bone-resorbing cells [11].
TRAP is a diﬀerent form of the enzyme acid phosphatase,
which is found mainly in bone and some blood cells.
TRAP is released during the bone-resorbing activity of
osteoclasts[26].Formeasurementoftheosteoclastnumbers,
histological sections were stained with TRAP. We counted
the numbers of osteoclasts in the region of the primary
spongiosa and found that the numbers decreased in the
FME-treated OVX rats. These ﬁndings support the idea
thatFMEcanameliorateovariectomy-inducedosteopeniaby
suppressing osteoclast diﬀerentiation (Figure 8).
Both ER receptors are expressed in osteoblasts, octeo-
clasts, and bone marrow stoma cells, indicating that both
ER receptors play a role in skeletal maturation and deter-
mination of bone mass [21]. Thus, it is possible that
FME ameliorate the osteoporosis in OVX rats through
the activation of both ER. Development of tissue-speciﬁc
selective ER modulators (SERM), such as those speciﬁc to
the skeleton, might alleviate some of the risk associated with
traditional estrogen therapy complicated by eﬀects in other
tissues. FME can maintain bone mass, but not eﬀect on
obesity and atrophy of vagina, indicating that FME exhibits
SERM-like eﬀects.
As a result of evidence that estrogen replacement or
bisphosphonates therapies are associated with increased
risk of cancer or osteonecrosis, respectively [27, 28]. It
is now generally recognized that alternative approaches to
the prevention and treatment of osteoporosis might be
worth exploring. Scientists have turned to explore the health
beneﬁts of plant-based bioactive compounds that have been
showntopositivelyinﬂuencebonemetabolism.Forinstance,
soy-based diets plus fructooligosaccharides, and Epimedium
brevicornum, a Chinese herbal medicine, have been shown
to improve bone mass in animal models of osteoporosis
[22, 29]. Therefore, we undertook this study to evaluate the
eﬃcacyofFME,aTaiwaneseherb,inpreventingosteoporosis
using the OVX model. Our study had shown that FME
exhibits antiosteoporotic eﬀects, suggesting that it may play
a promising role in the treatment of osteoporosis.
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